|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
310,240,000 |
Market
Cap: |
6.70(B) |
Last
Volume: |
2,209,901 |
Avg
Vol: |
2,443,625 |
52
Week Range: |
$18.78 - $24.13 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 14.9 |
Insider 6 Months : 16.6 |
Insider 3/6 Months : 32 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
2 |
2 |
2 |
Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
Total People Sold |
2 |
4 |
5 |
11 |
Total Sell Transactions |
2 |
8 |
12 |
26 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hessekiel Jeffrey |
EVP, General Counsel & Sec |
|
2023-12-13 |
4 |
AS |
$23.01 |
$575,250 |
D/D |
(25,000) |
533,345 |
|
-0% |
|
Haley Patrick J. |
EVP, Commercial |
|
2023-12-12 |
4 |
AS |
$22.50 |
$318,353 |
D/D |
(14,149) |
307,687 |
|
4% |
|
Hessekiel Jeffrey |
EVP, General Counsel & Sec |
|
2023-12-04 |
4 |
AS |
$22.06 |
$551,500 |
D/D |
(25,000) |
558,345 |
|
1% |
|
Hessekiel Jeffrey |
EVP, General Counsel & Sec |
|
2023-11-30 |
4 |
AS |
$22.01 |
$550,250 |
D/D |
(25,000) |
583,345 |
|
4% |
|
Caligan Partners Lp |
Director |
|
2023-11-27 |
4 |
B |
$21.61 |
$2,602,038 |
I/I |
120,409 |
910,730 |
2.1 |
8% |
|
Caligan Partners Lp |
Director |
|
2023-11-27 |
4 |
S |
$21.61 |
$2,602,038 |
I/I |
(120,409) |
790,321 |
|
-8% |
|
Morrissey Michael M |
President and CEO |
|
2023-11-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
19,020 |
1,436,914 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-11-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
116,893 |
1,455,934 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
116,893 |
610,000 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2023-09-06 |
4 |
D |
$22.27 |
$381,864 |
D/D |
(17,147) |
611,545 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2023-09-06 |
4 |
A |
$0.00 |
$0 |
D/D |
65,135 |
628,692 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-09-06 |
4 |
D |
$22.27 |
$1,037,960 |
D/D |
(46,608) |
726,893 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-09-06 |
4 |
A |
$0.00 |
$0 |
D/D |
188,005 |
773,501 |
|
- |
|
Hessekiel Jeffrey |
EVP, General Counsel & Sec |
|
2023-09-06 |
4 |
D |
$22.27 |
$319,664 |
D/D |
(14,354) |
608,345 |
|
- |
|
Hessekiel Jeffrey |
EVP, General Counsel & Sec |
|
2023-09-06 |
4 |
A |
$0.00 |
$0 |
D/D |
57,900 |
622,699 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2023-09-06 |
4 |
D |
$22.27 |
$319,664 |
D/D |
(14,354) |
321,836 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2023-09-06 |
4 |
A |
$0.00 |
$0 |
D/D |
57,900 |
336,190 |
|
- |
|
Aftab Dana |
CSO/EVP Disc & Trans Research |
|
2023-09-06 |
4 |
D |
$22.27 |
$279,711 |
D/D |
(12,560) |
438,043 |
|
- |
|
Aftab Dana |
CSO/EVP Disc & Trans Research |
|
2023-09-06 |
4 |
A |
$0.00 |
$0 |
D/D |
50,660 |
450,603 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-09-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
57,500 |
1,339,041 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-08-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
56,221 |
1,396,541 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-08-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
56,221 |
585,496 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-08-28 |
4 |
D |
$22.18 |
$6,737,818 |
D/D |
(303,779) |
641,717 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2023-08-28 |
4 |
OE |
$15.31 |
$5,511,600 |
D/D |
360,000 |
945,496 |
|
- |
|
Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
|
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
240,000 |
240,000 |
|
- |
|
1414 Records found
|
|
Page 2 of 57 |
|
|